# Targeting CD157 in AML using a novel, Fc-engineered antibody construct

Supplementary Materials

Supplementary Figure 1: CD157 expression intensity (MFI ratio) compared to CD33 in 101 primary AML patient samples.

Supplementary Figure 2: Correlation of CD157 expression to molecular and cytogenetic characteristics in AML.
(**A**) The patient cohort was divided into two halves based on expression intensity for correlation to (**B**) genetic risk groups according to the European Leukemia Net (ELN) classification and (**C**) to mutations in the *NPM1* and *FLT3* gene.